← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Cellectis CLLS $111M	57	+15	+36%	$213M
52	52 Neurogene NGNE $478M	52	+9	+21%	$253M
53	53 Arbutus Biopharma ABUS $842M	51	-2	-4%	$173M
54	54 Vericel Corp VCEL $2.11B	50	+10	+25%	$73.4M
55	ATNX 55 DELISTED Athenex, Inc. Common Stock ATNX	45	+12	+36%	$59.1M
56	56 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	40	+2	+5%	$10.7M
57	57 Pluri PLUR $12.1M	39	+6	+18%	$6.37M
58	58 Cibus CBUS $98.6M	38	+3	+9%	$136M
59	59 DELISTED BRAINSTORM CELL THERAPUTC BCLI	35	+3	+9%	$7.11M
60	ONCS 60 DELISTED OncoSec Medical Incorporated ONCS	34	+14	+70%	$7.3M
61	61 Rocket Pharmaceuticals RCKT $250M	34	-1	-3%	$32.1M
62	62 DELISTED BioLife Solutions BLFS	31	+7	+29%	$10.3M
63	PTE 63 DELISTED PolarityTE, Inc. Common Stock PTE	30	+8	+36%	$18.8M
64	64 Opus Genetics IRD $333M	28	+7	+33%	$3.28M
65	65 ProQR Therapeutics PRQR $207M	27	+4	+17%	$37.1M
66	66 Ocugen OCGN $275M	25	+5	+25%	$25.2M
67	67 DELISTED Carisma Therapeutics CARM	23	+1	+5%	$5.39M
68	68 Capricor Therapeutics CAPR $423M	22	+3	+16%	$3.84M
69	69 Imunon IMNN $5.95M	20	+9	+82%	$1.82M
70	70 Mesoblast MESO $1.8B	20	+2	+11%	$15.8M
71	71 DELISTED DermTech, Inc. Common Stock DMTK	19	+7	+58%	$89.1M
72	72 ARK Genomic Revolution ETF ARKG $2.07B	18	+5	+38%	$7.86M
73	73 Fulgent Genetics FLGT $587M	18	-3	-14%	$6.2M
74	HTGM 74 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	17	-4	-19%	$4.18M
75	75 Krystal Biotech KRYS $9.85B	13	0	0%	$34M